Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM
Diabetes Ther
.
2021 Jun;12(6):1765-1768.
doi: 10.1007/s13300-021-01073-3.
Authors
Ichiro Nakamura
1
,
Hiroshi Maegawa
2
,
Kazuyuki Tobe
3
,
Satoshi Uno
4
Affiliations
1
Operational Excellence, Medical Affairs Japan, Astellas Pharma Inc., Tokyo, Japan. ichiro.nakamura@astellas.com.
2
Department of Medicine, Shiga University of Medical Science, Shiga, Japan.
3
First Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan.
4
Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.
PMID:
34018149
PMCID:
PMC8179875
DOI:
10.1007/s13300-021-01073-3
No abstract available
Publication types
Published Erratum